RECRUITING Phase 3 ClinicalTrials.gov

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Sponsor: Vantive Health LLC • ClinicalTrials.gov ID: NCT05399537

Registry updated: 2026-10-05

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.

Interventions

Prismocitrate 18 (Drug)
Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
PrisMax System Version 3.x with calcium line accessory (Device)
The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.

Eligibility criteria

Inclusion Criteria: * Patients must be ≥18 years of age * Patients who are candidates for CRRT * Patients expected to survive for at least 24 hours * Patients with a contraindication to heparin or an increased risk of hemorrhage * Patient and/or legally-authorized representative has signed a written informed consent form (ICF) per 21 CFR Part 50.55(e) Exclusion Criteria: * Patients with a known allergy to citrate or who have ever experienced an adverse reaction associated with citrate products, including patients with a prior history of citrate toxicity * Patients with acute liver failure, defined by the occurrence of encephalopathy and hepatic synthetic dysfunction within 26 weeks of the first symptoms of liver disease and without evidence of chronic liver disease * Patients with acute-on-chronic liver failure characterized by acute decompensation of cirrhosis and a Child-Pugh Liver Failure Score \>10 * Patients with refractory shock and associated lactic acidosis (lactate \>4 mmol/L) * Patients with a systemic ionized calcium concentration outside the normal physiologic range (1.0 - 1.3 mmol/L), or outside of the laboratory reference range (Note: It is acceptable to provide calcium supplementation or treatment for hypercalcemia to achieve a normal physiologic range prior to therapy initiation) * Female patients of childbearing potential who are pregnant or breastfeeding. (Note: All female patients, who have not undergone a hysterectomy, bilateral oophorectomy with or without hysterectomy, or has medically documented ovarian failure before study Screening must have a negative serum beta human chorionic gonadotropic \[B-hCG\] pregnancy test at Screening) * Patients who are currently participating in another interventional clinical study

Conditions

Regional Citrate Anticoagulation (RCA) Continuous Renal Replacement Therapy (CRRT) Acute Kidney Injury (AKI)

Locations

University of Alabama at Birmingham/UAB — Birmingham, Alabama, United States
University of Southern California (USC) / Keck Hospital — Los Angeles, California, United States
University of California Los Angeles — Los Angeles, California, United States
University of Miami — Miami, Florida, United States
Emory University — Atlanta, Georgia, United States
University of Michigan — Ann Arbor, Michigan, United States
Bon Secours Mercy Health-Springfield Regional Medical Center — Springfield, Ohio, United States
Geisinger Medical Center — Danville, Pennsylvania, United States
Penn State Hershey Medical Center — Hershey, Pennsylvania, United States
VA Pittsburgh Healthcare System — Pittsburgh, Pennsylvania, United States
Medical University of South Carolina (MUSC) — Charleston, South Carolina, United States
Lt. Col. Luke Weathers, Jr. VA Medical Center — Memphis, Tennessee, United States
Methodist Dallas Medical Center — Dallas, Texas, United States
Gamma Medical Research, Inc / McAllen Medical Center — McAllen, Texas, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment